Vital Art and Science announced that it has signed a license agreement with Genentech for the use of Vital Art and Science’s mVT App service in Genentech’s ophthalmology clinical studies. Under the terms of the agreement, Genentech intends to use the App service to enhance patient experience, improve the effectiveness of patient‘s interactions with health care providers and apply the data collected through the App service to improve patient care and clinical trial design.
The mVT App is currently being used in Genentech’s phase 2 LADDER study (NCT02510794) investigating the sustained delivery of Lucentis (ranibizumab injection) via Genentech’s Port Delivery System, in patients with wet age-related macular degeneration (AMD). Patients will be testing their vision using the mVT service during their in-clinic appointment and at home (remote vision monitoring).
The agreement builds on the prior collaboration between Genentech and Vital Art and Science, under which Genentech used the mVT Service as part of its PIVOT Study (Patient-centric Innovative Vision Home Testing).
“This agreement is the successful continuation of an ongoing collaboration between the teams at Vital Art and Science and Genentech," Mike Bartlett, President and CEO, Vital Art and Science, said in a company news release. "We believe that Genentech, a leader in ophthalmic drug development, is a strong partner for the mVT Service that will drive more retina specialists and other ophthalmic drug companies to adopt as the next industry standard for vision monitoring in between office assessments.”
About the mVT Service
The mVT Service is currently commercially available to retina specialists for patients with maculopathy, including dry and wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, macular pucker, macular hole, retinal vein occlusion/branch retinal vein occlusion, and more. The mVT App is available on both iOS and select Android devices and detects both vision worsening and improvement. Patients can test their vision as often as they wish, but are recommended to do so at least twice a week. The testing procedure is very user-friendly; four shapes are displayed on the screen and the patient chooses the shape that looks different. The test is untimed, has no fixed distance, and includes test-retest variability to reduce the number of false positives. There are three types of patients seen by retina specialists who may benefit from home vision monitoring:
1. The patient who is diagnosed early and has not yet started treatment, but is considered high risk. Such patients may benefit from the mVT Service because the vision monitoring results and alerts are shared with the physician before the patient's next appointment. Consequently, the mVT Service acts as a safety net that can alert the physician as soon as their patient’s vision has worsened by greater than +0.2 LogMAR from baseline.
2. Patients receiving treatment in at least one eye. The benefit of monitoring such patients during treatment is that the physician is able to better understand if the patient is responding to the selected anti-VEGF injection. In addition, the physician is able to monitor the patient’s other eye.
3. Patients in the treat-and-extend phase. The mVT Service again acts as a safety net and notifies the physician whenever the patient’s vision has worsened to an extent greater or equal to +0.2LogMAR. Early detection can lead to earlier physician assessments and treatment.
Retina Specialists and clinics who are interested in providing home vision monitoring to their patients can go to their website to register and sign up to be a prescriber.